BRUSSELS, June 26 (Reuters) - Europe's drug watchdog has recommended EU approval of UCB SA's Cimzia drug as a treatment for rheumatoid arthritis, the Belgian company said on Friday, clearing the way ...

BRUSSELS, March 28, 2019 /PRNewswire/ -- UCB, a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved extending the label for CIMZIA (®) ...

BARCELONA, June 14 (Reuters) - UCB SA's experimental arthritis treatment Cimzia could be priced at a discount to rivals, since the drug has lower production costs, a key scientific investigator on the ...

ATLANTA, Oct. 18, 2013 -- regulated information – UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Cimzia® (certolizumab pegol) for the treatment of adults with active ...

UCB's CIMZIA® (certolizumab pegol) approved by the U.S. FDA for adult patients suffering from moderate to severe rheumatoid arthritis Available this week, Cimzia® (certolizumab pegol), the only ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/724zq9/cimzia) has announced the addition of the "Cimzia (certolizumab pegol ...

Cost regulators for the NHS in England and Wales are recommending UCB's Cimzia and Novartis' Cosentyx as treatment options for adults with active psoriatic arthritis. Cost regulators for the NHS in ...

LONDON (MarketWatch) -- UCB said it's going to have another short-term study of its Cimzia drug in which it will confirm the induction of clinical response in moderate to severe active Crohn's disease ...

UCB announced results from the Phase 3 RAPID-PsA study which showed that compared to placebo, certolizumab pegol (Cimzia) provided improvements in the signs and symptoms of psoriatic arthritis (PsA) ...

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called non-radiographic axial ...

BRUSSELS — The Food and Drug Administration has approved a new usage for a drug made by UCB, the drug maker said Monday. UCB announced the approval of Cimzia (certolizumab pegol) for psoriatic ...